Do You Still Lose Weight on a Maintenance Dose of Wegovy?

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Most people taking semaglutide move through a four-to-eight-week dose escalation before reaching a stable maintenance dose. Once you stabilize at that dose, weight loss doesn't automatically plateau—but the pattern changes. Clinical data shows continued weight reduction is possible, though the trajectory differs from the rapid losses seen early in treatment.

How Semaglutide Works During Maintenance Phase

During dose escalation, your body responds to increasing GLP-1 receptor activation with significant appetite suppression and metabolic shifts. Once you reach maintenance—typically 1.0 to 2.4 mg weekly for injected semaglutide—your system has adapted to that steady hormone level. This adaptation doesn't eliminate the drug's effect; it means your body has achieved a new hormonal baseline where hunger signals remain suppressed and satiety signals remain enhanced.

At maintenance, semaglutide continues reducing your desire to eat by slowing stomach emptying and increasing feelings of fullness from smaller portions. The medication also influences glucose homeostasis and may subtly increase energy expenditure, though the appetite-suppression mechanism remains the primary driver of weight loss. This sustained mechanism explains why many patients report continued gradual weight loss even after reaching their target dose.

Expected Weight Loss Trajectory After Reaching Maintenance

Clinical trials of semaglutide show that weight loss velocity typically slows once a maintenance dose is established, compared to the escalation phase. Patients often experience rapid loss during weeks 1-12, then a more gradual decline from week 12 onward as the dose levels and the body's metabolic adaptation occurs. The majority of semaglutide users continue losing 0.5 to 1.5 pounds per week at maintenance, though individual results vary significantly based on adherence, diet, activity, and genetic factors.

Some patients experience a plateau at maintenance where weight stabilizes rather than continues declining. This plateau can last weeks or months before additional losses resume. Other patients report steady, predictable losses throughout their treatment journey. These differences often reflect how your individual genetic pathways respond to GLP-1 signaling—a key reason PlexusDx offers the Precision Peptide Genetic Test to map your specific peptide-pathway vulnerabilities and receptor sensitivity.

Factors That Determine Continued Weight Loss at Maintenance

Your genetic makeup significantly influences how your body responds to semaglutide at any dose level. Variants in the GLP1R gene (such as rs6923761) affect how efficiently your GLP-1 receptors respond to medication. Variants in the FTO gene (rs9939609) and MC4R gene (rs17782313) influence appetite regulation and energy balance independent of GLP-1 signaling. Patients with favorable genetic profiles in these pathways often experience sustained weight loss, while those with less-responsive variants may need optimization strategies.

Beyond genetics, diet composition, exercise frequency, sleep quality, and stress levels all affect maintenance-phase weight loss. Semaglutide reduces appetite but doesn't prevent overeating if calorie intake remains elevated or if volume overconsumption continues despite fullness signals. Patients who combine medication with moderate dietary adjustments and physical activity consistently report better sustained weight loss than those relying solely on medication. Alcohol consumption, certain medications (like corticosteroids), and metabolic conditions like thyroid dysfunction can also influence your trajectory.

Optimizing Your Semaglutide Maintenance Strategy

If your weight loss slows at maintenance, several approaches can restore progress. The first is examining adherence: missing doses or inconsistent injection timing reduces the medication's effectiveness. The second is reassessing nutrition—even with appetite suppression, consuming high-calorie foods or large volumes can limit results. The third is considering whether your current dose is truly optimal for your body, though dose increases beyond 2.4 mg weekly are uncommon and require medical oversight.

PlexusDx offers the Precision Peptide Genetic Test to identify which of your 14 key peptide pathways most influence your weight and metabolism. This test reveals your genetic predispositions across GLP-1 signaling, GIPR function, energy expenditure, and appetite-control mechanisms. Armed with this data, you and your provider can make informed decisions about whether semaglutide alone is your optimal therapy, whether an alternative like tirzepatide (which targets both GLP-1 and GIP receptors) might be more effective, or whether combination protocols like GLP-Squared could accelerate results. PlexusDx Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan), with pricing flat regardless of your dose level—a structure that keeps your cost stable as your treatment evolves.

When to Expect a Weight-Loss Plateau and How to Overcome It

A maintenance-phase plateau typically occurs after three to nine months, when your body's metabolic adaptation reaches equilibrium with your current dose. During this time, weight may not change for four to eight weeks, which is normal and does not indicate treatment failure. Plateaus are part of the natural weight-loss trajectory and often resolve spontaneously as your body continues adjusting, or as your eating patterns stabilize at a lower intake level.

To move past a plateau, first confirm you're not unconsciously increasing portion sizes as appetite suppression adapts. Reviewing a food diary for one week often reveals unexpected calorie creep. Second, introduce or increase physical activity—adding 30 minutes of moderate-intensity exercise three times weekly can restart weight loss even at a stable dose. Third, discuss with your provider whether your current dose remains optimal or whether a slight adjustment, medication change, or combination therapy could help. PlexusDx supports all 50 states with licensed 503A compounding pharmacies, so switching between semaglutide injection, oral semaglutide, tirzepatide, or dual-compound options like GLP-Squared is straightforward and doesn't require insurance.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Do you still lose weight once you reach your maintenance semaglutide dose?

Yes, most patients continue losing weight at maintenance, though the rate typically slows compared to the dose-escalation phase. Clinical data shows continued gradual weight loss is common, with many patients losing 0.5 to 1.5 pounds weekly at stable doses. Individual results vary based on genetics, diet adherence, and lifestyle factors.

Why does weight loss slow down once semaglutide reaches maintenance?

Your body adapts to a steady hormone level, reducing some of the dramatic appetite suppression seen during dose escalation. This doesn't mean the medication stops working—it means the suppression becomes your new normal. Additionally, metabolic adaptation and behavioral factors (like unconsciously increasing portion sizes) contribute to slower losses over time.

How much weight can I expect to lose on a semaglutide maintenance dose?

Clinical trials show average total weight loss of 15-22% of baseline body weight over 68 weeks with semaglutide. At maintenance, you may lose 0.5-1.5 pounds weekly, though some patients experience plateaus lasting weeks before additional losses resume. Your individual response depends on genetics, diet quality, physical activity, and medication adherence.

What should I do if my weight loss stops at semaglutide maintenance?

Review adherence, diet patterns (check for calorie creep), and physical activity levels. If these are optimized, discuss with your provider about confirming your dose is appropriate or exploring whether a different medication or combination therapy might better match your genetic pathway response. PlexusDx can help clarify your individual physiology through the Precision Peptide Genetic Test ($298).

Could my genes affect whether I lose weight on a semaglutide maintenance dose?

Absolutely. Variants in GIPR, FTO, and MC4R genes directly influence how your body responds to semaglutide. PlexusDx maps 14 peptide pathways and 150+ genetic insights to reveal your individual predispositions, helping determine whether semaglutide is optimal or whether alternatives like tirzepatide might be more effective for your biology.

Is compounded semaglutide from PlexusDx as effective as branded Wegovy?

Compounded semaglutide from licensed 503A pharmacies contains the same active ingredient (semaglutide) as branded versions. Effectiveness depends on dose, adherence, and individual factors—not whether the medication is branded or compounded. PlexusDx sources from licensed 503A compounders and serves all 50 states at $189/mo month-to-month, or from $149/mo on the 6-month plan with no insurance required.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Wegovy For Losing Weight

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.